You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Medications Research Articles
A Danish study of 107,806 adults taking various diabetes medications has found that three drugs are the most effective at lowering the risk of cardiovascular disease and death: metformin, gliclazide (not marketed in the US), and repaglinide (Prandin). Other common diabetes medications, including glimepiride, glibenclamide (glyburide), glipizide, and tolbutamide, were linked to a higher risk of death both from all causes and from heart attack and stroke.
1 comment - Posted May 13, 2011
Taking your medicine can lead to quite a windfall in reduced medical claims, according to a study recently published in Health Affairs. Over the course of a year, patients with diabetes who took their medications as directed saved their insurance companies a handsome $3,756 compared to people who didn't, even after claiming as much as $1000 for those very medications. The money was saved because the patients spent less time at the emergency room and in the hospital, a nice benefit in itself.
1 comment - Posted Jan 11, 2011
Sitagliptin (Januvia) has long been used to reduce blood sugar in people with type 2 diabetes, but a new study indicates that it can do the same for those with type 1 diabetes. Sitagliptin is a DPP-4 inhibitor; that is, it inhibits, or temporarily prevents, the enzyme DPP-4 from destroying a helpful hormone called GLP-1. GLP-1, which is released by the gut when food arrives there from the stomach, lowers blood sugar by causing the release of insulin, reducing the secretion of glucagon, and slowing stomach emptying and nutrient absorption.
3 comments - Posted Jan 7, 2011
My trip began as I flew from Dallas to my home town of Philadelphia and then caught an early Amtrak train to New York City. Growing up in the Philadelphia area had given me an appreciation for U.S. history, but today I was going to learn something new: the history of diabetes. My daughter, Sarah, was diagnosed with type 1 diabetes in 2003, yet I didn't know much about the history of the disease. Living every day with the stress and worry that many parents have, I felt I had no time to spend learning how we got to the modern treatments we have today. I had focused only on doing my job as caregiver and supporter of my daughter. I was looking forward to learning something new.
10 comments - Posted Jan 3, 2011
A new study finds that combining the newer diabetes drug exenatide with insulin provides better blood sugar control in patients with type 2 diabetes than insulin alone and helps promote weight loss.
1 comment - Posted Dec 27, 2010
A new drug for type 2 diabetes started showing up in drugstores this week, according to manufacturer Santarus. The FDA-approved drug, called Cycloset, takes an distinctive -- and not well understood -- approach to reducing blood sugar levels. The pill apparently works by increasing dopamine activity in the hypothalamus, a part of the brain. Dopamine is a brain chemical that plays a big role in people's behavior, mood, and ability to sleep. Scientists theorize that glucose intolerance and insulin resistance may in part result from abnormal activity of this chemical, and that upping dopamine activity may iron out these problems.That's the theory, at least: the drug's exact workings aren't known. But it seems to do the trick.
0 comments - Posted Nov 24, 2010
"The objective of this clinical trial (research study) is to determine if the medications can rescue the few beta cells that remain soon after the diagnosis of type 1 diabetes; and whether new beta cells can even be regenerated," commented Alex Rabinovitch, MD, Principal Investigator of the trial and Associate Director of The Sanford Project. "The investigational combinations of these medications could possibly allow patients to decrease or no longer need to inject insulin to keep their blood levels under proper control."
0 comments - Posted Aug 12, 2010
And wouldn't it be great if that pill weren't something advertised on late-night TV, but rather a legitimate treatment? A drug called rimonabant, introduced in Europe, seemed to fit the bill at first, but it was pulled from the market in late 2008 due to concerns about psychiatric side effects.
0 comments - Posted Aug 10, 2010
Novo Nordisk presented results demonstrating that once-daily Victoza® (liraglutide [rDNA] injection) achieved significantly greater improvements in blood sugar control compared to placebo among African-American patients with type 2 diabetes. The meta-analysis of phase 3 data from the Liraglutide Effect and Action in Diabetes (LEAD) trials were presented at the 2010 National Medical Association Annual Convention & Scientific Assembly.
0 comments - Posted Aug 5, 2010
(Reuters) - The first new prescription weight-loss pill in more than a decade failed to win backing from U.S.health advisers, who said safety concerns about the drug outweighed its ability to help obese patients shed pounds.
0 comments - Posted Jul 19, 2010
The U.S. Food and Drug Administration's (FDA) Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee has completed their evaluation of the scientific research available on the safety of rosiglitazone. The deliberations of the panel reflected the complexity of the issues, with several members voting to add additional warnings or to withdraw the drug from the U.S. market. Ultimately, the final recommendation was to allow Avandia to remain on the market. Now that the expert panel has concluded its meeting, the FDA will review their recommendations and make the final decision on whether the drug remains available to patients.
0 comments - Posted Jul 15, 2010
Having discovered a dramatic increase of an easy-to-detect enzyme in the red blood cells of people with diabetes and pre-diabetes, Johns Hopkins scientists say the discovery could lead to a simple, routine test for detecting the subtle onset of the disease, before symptoms or complications occur and in time to reverse its course.
0 comments - Posted Jul 15, 2010
Data from the massive ACCORD study on intensive blood sugar control shows that lowering blood sugar levels in people with longstanding type 2 diabetes to near-normal may delay the appearance of signs that point to damage to nerves, eyes, and kidneys, but does not stop their progression toward it.
0 comments - Posted Jul 9, 2010
A study released in late June has brought some welcome news to the makers of Byetta and Januvia: Users of the two diabetes drugs run no greater risk of developing pancreatitis than people with diabetes who take other drugs. In fact, both drugs seem to put users at slightly less risk for the condition.
0 comments - Posted Jul 8, 2010
AFREZZA TM (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, investigational ultra rapid acting mealtime insulin, as part of a diabetes treatment regimen, provides long-term glucose control comparable to usual insulin therapy but with a significantly reduced incidence of hypoglycemia and less weight gain in patients with Type 2 diabetes, according to a two-year study presented at the American Diabetes Association's 70th Scientific Sessions.
0 comments - Posted Jul 6, 2010
Depomed, Inc. and Santarus, Inc. announced new data suggesting that patients previously intolerant of metformin may be able to tolerate higher doses of metformin when treated with GLUMETZA® (metformin HCl extended release tablets). The finding will be presented at the 70th Scientific Sessions of the American Diabetes Association (ADA) in Orlando. GLUMETZA is a once-daily, extended release formulation of metformin, and is approved for use in adults with type 2 diabetes mellitus. It is promoted in the U.S. by Santarus.
0 comments - Posted Jul 1, 2010
New guidelines from the American Diabetes Association and two other major medical associations advise not prescribing low-dose aspirin therapy for women under 60 or men under 50 who have diabetes but no other risks for heart disease.
0 comments - Posted Jun 12, 2010
Results from a Phase 3 study demonstrate MACUGEN® (pegaptanib sodium) significantly improved vision in patients with diabetic macular edema (DME), a complication of diabetes that is a leading cause of blindness in people of working age.¹ In the study, 37 percent of patients treated with MACUGEN gained two lines, or 10 letters, of vision on the ETDRS eye chart at 54 weeks, compared to 20 percent of patients who received a sham (placebo-like) procedure which consists of anesthesia and a simulated injection in the eye (p=0.0047). The data were presented at the World Ophthalmology Congress in Berlin by Frank G. Holz, an investigator in the trial and director of the University Eye Hospital at the University of Bonn in Germany.
0 comments - Posted Jun 7, 2010
Scientists at the Mayo Clinic have developed a molecule that can block the breakdown of insulin. Their discovery could lead to development of a new class of drugs to help treat diabetes.
0 comments - Posted May 10, 2010
CINCINNATI - The popular diabetes medication metformin works in different fashion than the current widely accepted view. This new finding could lead to wider use of the drug-particularly in people with cancer.
1 comment - Posted May 4, 2010
The study, published in the journal Diabetes Care, adds to evidence that metformin, a generically available drug commonly used for type 2 diabetes, may have anti-cancer effects.
0 comments - Posted Apr 22, 2010
Tests of an experimental drug called CPSI-1306 at Ohio State University were so successful at lowering inflammation and blood sugar levels in lab mice with type 2 diabetes that scientists consider it a prime candidate to become a new therapy for the disease.
0 comments - Posted Apr 8, 2010
Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan (Diovan) delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.
0 comments - Posted Mar 20, 2010
According to Duke University researchers, a mutation that causes the lack of an insulin-controlling molecule may be a factor in the development of type 2 diabetes. The molecule, ankyrin B, is activated in response to the smell and taste of food and leads to the production of insulin in preparation for food intake.
1 comment - Posted Mar 19, 2010
A scientist's discovery that dolphins have a genetic ability to turn diabetes on and off, depending on the availability of food, could lead to research into whether humans might have a similar-although dormant-gene.
1 comment - Posted Mar 13, 2010
Santa Clara County, the largest county in Northern California (nearly 1.9 million people), has filed a federal lawsuit against pharmaceutical company GlaxoSmithKline, alleging that Glaxo knowingly sold its type 2 diabetes drug Avandia for several years despite indications the drug causes heart attacks and strokes.
0 comments - Posted Mar 8, 2010
A U.S. Senate Finance Committee report released on February 20 says that Avandia, GlaxoSmithKline's drug for type 2 diabetes, may have caused as many as 83,000 heart attacks between 1999, when the drug was introduced, and 2007. The Senate report, culminating a two-year inquiry into the drug, also says that Glaxo knew about the drug's potential risks years before suspicions began to form regarding a connection between Avandia and heart problems.
2 comments - Posted Feb 22, 2010
FRIDAY, Dec. 18 (HealthDay News) -- Blacks tend to carry around less of a particularly unhealthy type of abdominal fat than whites, even though they suffer more from obesity-linked illness, researchers report.
0 comments - Posted Dec 23, 2009
WORCESTER, Mass., Dec 3, 2009 (GlobeNewswire via COMTEX News Network) -- Published in the journal Diabetes, Obesity and Metabolism, an independent review of clinical trials of Generex Oral-lyn(TM) shows that the oral insulin spray has a faster onset of action and shorter duration of action than insulin delivered subcutaneously.
6 comments - Posted Dec 9, 2009
A Swedish biotechnology company, TikoMed AB, has received notice that the U.S. Food and Drug Administration is granting orphan drug designation to its IBsolvMIR® drug for preventing the rejection of transplanted pancreatic islet cells in type 1 patients.
0 comments - Posted Dec 4, 2009
So close, and yet so far. It looks like there will be no marketing partnership for MannKind's ultra rapid-acting insulin product Afresa anytime soon. The company had planned to enter into a deal with a large pharmaceutical company by the end of this year, but now approval from the Food and Drug Administration (FDA) for their inhaled insulin won't be until January 2010, at the earliest.
3 comments - Posted Oct 8, 2009
The demise of Fen-phen dealt a body blow to hopes for an obesity pill that is actually effective. Unfortunately, the fen in Fen-phen, fenfluramine, caused grave pulmonary hypertension and heart valve problems. The phen part of the drug, though, was apparently just an innocent bystander. And now phen (phentermine) has resurfaced in a new pill that has posted some amazing results in Phase III clinical trials. Patients who were treated for 56 weeks with the new drug, Qnexa, lost an average of 14.7 percent of their weight, or 37 pounds.
8 comments - Posted Oct 7, 2009
A study coming out in the November issue of the Clinical Journal of the American Society of Nephrology is reporting that type 2 men whose blood contained a high count of eosinophils, a sign of allergic inflammation, also had albumin in their urine, which is an early indication of kidney disease. Eosinophils are white blood cells that increase in number during an allergic reaction. Albumin is a protein in the blood that helps regulate blood volume and acts as a carrier for other molecules. Albumin is not normally found in the urine, however, because when healthy kidneys filter the blood, they retain what the body needs (like proteins) and allow only smaller "impurities" into the urine. But during diabetes, too much blood sugar can damage the filtering structures of the kidneys, causing them to thicken and become scarred. Eventually, they begin to leak, and protein (albumin) begins to pass into the urine.
0 comments - Posted Oct 6, 2009
The enthusiasm for inhaled insulin has waned, to say the least, since Exubera was pulled off the market by Pfizer. Following the Exubera debacle, the development of two other inhaled insulins (AIR by Eli Lilly and Alkermes, and AERx by Novo Nordisk) was halted as well.
14 comments - Posted Oct 5, 2009
Metformin has always been the old reliable for treating new onset type 2 diabetes, but it's beginning to look like it's got a new calling as a cancer treatment. Diabetes Health recently reported on the fact that metformin reduces a type 2 person's risk of pancreatic cancer by up to 62 percent. It's also been observed that people with type 2 who take metformin have a much lower cancer incidence than those who don't. Now it appears that metformin can help with breast cancer treatment as well. A study of mice with breast cancer generated from human breast cancer cells has found that they remained tumor-free for nearly three months on metformin combined with doxorubicin, a standard cancer chemotherapy. In mice given only the doxorubicin, the tumors recurred.
1 comment - Posted Sep 25, 2009
A new glucagon-like peptide-1 (GLP-1) analog for type 2s that might require dosing only once a month is now in pre-clinical (animal) studies. GLP-1, which increases insulin secretion from the pancreas, is a mighty helpful molecule, but with a sadly brief lifespan. It's broken down in the body within minutes by the enzyme DPP-4. That's why drugs like Merck's Januvia, a DPP-4 inhibitor, is effective: blocking DPP-4 subsequently increases the amount of GLP-1 in the system.
0 comments - Posted Aug 25, 2009
According to results of a phase II clinical trial at the University of Texas Medical School, a low dose of oral interferon alpha can preserve pancreatic beta cell function in newly diagnosed type 1 diabetes patients. Interferons are proteins produced by the cells of the immune system in response to challenges like a virus or a tumor cell. They work by inhibiting viral replication in the host cell, activating natural killer cells, and increasing the activity of other immune system cells such as lymphocytes.
0 comments - Posted Jul 24, 2009
An analysis of ten trials involving statin therapy among 70,000 participants has led an international team of cardiologists to recommend that that the cholesterol-lowering drugs be prescribed for people who do not have heart disease.
2 comments - Posted Jul 15, 2009
Scientists have identified five genetic biomarkers that predict how well a type 2 patient will respond to the drug Actos. Their work could be the first step toward a system that would allow doctors to predetermine which drugs will best help each person with diabetes.
0 comments - Posted Jul 3, 2009
Genentech, a bioscience firm famous for its development of antibodies designed to combat cancer, has entered a $350 million agreement with Bayhill Therapeutics to assist in development of BHT-3021, a drug that treats type 1 diabetes by reducing or stopping immune system attacks on pancreatic beta cells.
2 comments - Posted Jul 1, 2009
Patients with type 2 diabetes reduced their risk of having a foot amputated by 36 percent when they took fenofibrate, a drug designed to lower blood fat levels.
0 comments - Posted Jun 12, 2009
Spanish university researchers have isolated a new species of bacteria-which they found in sewer sludge-that is able to break down cholesterol.
0 comments - Posted Jun 4, 2009
CRx-401, an insulin sensitizer intended to assist metformin in type 2 diabetes therapy, has successfully completed a Phase 2 clinical trial in which patients taking it saw their fasting plasma glucose drop by 12 mg/dl after 90 days.
1 comment - Posted Jun 3, 2009
Humanin (HN) is a mitochondrial peptide* that in some research has shown the ability to protect against the death of neurons, the devastating consequence of diseases like Alzheimer's. According to the leader of a research team at the Albert Einstein College of Medicine at Yeshiva University in the Bronx, however, it also significantly improves the insulin sensitivity of diabetic rats and sharply drops their glucose levels.
2 comments - Posted May 20, 2009
Dental researchers are reporting that resolvins, products derived from omega-3 fatty acids, may have the ability to restore the soft tissue and even bone lost in periodontal (gum) disease.
0 comments - Posted May 7, 2009
The European Union's drug regulation agency has recommended that the EU approve the marketing of "Victoza" (liraglutide), a type 2 drug developed by Novo Nordisk.
2 comments - Posted May 6, 2009
Voglibose*, a generic drug often used in combination with sulfonylureas to control blood glucose levels, appears to delay or even prevent the onset of diabetes in people who are predisposed to the disease.
6 comments - Posted May 1, 2009
Buoyed by its recent successful phase 1 human clinical trial of a patch that delivers basal insulin through the skin, Atlanta-based Altea Therapeutics says it will work with Eli Lilly and Company and Amylin Pharmaceuticals, Inc., to develop a daily transdermal patch that deliver sustained levels of Byetta (exenatide). The patch, in a 12- and a 24-hour form, will use the company's proprietary PassPort Transdermal Delivery System. Lilly and Amylin will fund all development, manufacturing, and marketing activities for the product.
2 comments - Posted Apr 7, 2009
Last week we published an article about how the CDC says too many people are still smoking. The federal government has a Healthy People 2010 goal of reducing adult smoking rates to 12 percent or less by 2010. Of the 50 states, only Utah has thus far achieved that goal.
1 comment - Posted Apr 2, 2009
New guidelines from the U.S. Preventive Services Task Force state that daily low doses of aspirin-75 milligrams to 81 milligrams-are as effective as higher doses (100+ milligrams) in preventing heart attacks among men and strokes among women.
3 comments - Posted Mar 26, 2009
Physicians who treat people with type 2 diabetes face difficult choices when selecting the best medical therapy for each patient. The decision process is further complicated by the fact that because type 2 diabetes is a progressive disease, therapeutic agents that were initially successful may fail five or ten years later.
166 comments - Posted Mar 20, 2009
Researchers funded by the Juvenile Diabetes Research Foundation have found two chemical compounds that can trigger the growth of insulin-producing beta cells in the pancreas. The discovery could become the basis for medicines designed to regenerate the pancreas in people with type 1 diabetes.
9 comments - Posted Mar 11, 2009
A complex sugar derived from glucose during the body’s metabolic processes could be a way to reliably detect a pre-diabetes condition, say researchers at the Johns Hopkins University School of Medicine in Baltimore. If it does, the “biomarker” (an indicator of an organism’s state of health) could provide enough early warning that patients nearing the onset of type 2 diabetes could take steps to slow or even halt it through lifestyle changes.
1 comment - Posted Mar 3, 2009
A report in the February 4, 2009, issue of Cell Metabolism says that babies born with neonatal diabetes might be able to avoid irreversible damage to the pancreas if doctors treat them quickly with sulfonylureas rather than insulin.
0 comments - Posted Feb 25, 2009
Georgia researchers believe that a powerful enzyme that inhibits or modifies immune system response could be the basis for a vaccine administered to children at high risk for developing type 1 diabetes.
0 comments - Posted Feb 25, 2009
Avanafil, a pill that may permit diabetic men who are experiencing erectile dysfunction to engage in intercourse without the restrictions on food or alcoholic intake associated with other ED treatments, is entering a second phase 3 study-the crucial step before a drug manufacturer seeks FDA or European approval to market.
5 comments - Posted Feb 24, 2009
Data from a phase 3 study of the Novo Nordisk drug liraglutide shows that when it is used in combination with glimepiride, it is more effective at reducing A1c's than glimepiride by itself or glimepiride in combination with the drug rosiglitazone.
0 comments - Posted Feb 19, 2009
By introducing a protein called cdk6 into human insulin-producing adult beta cells via a virus, University of Pittsburgh School of Medicine researchers have induced the cells to replicate "robustly." Previously, scientists believed that beta cells could be induced to regenerate slowly at best, and usually not at all.
0 comments - Posted Feb 5, 2009
We first reported on salsalate, an aspirin-like drug discovered in the nineteenth century, last October. At that time, researchers at the Joslin Diabetes Center in Boston discovered that it appears to reduce inflammation and lower blood glucose in people with type 2 diabetes.
2 comments - Posted Jan 27, 2009
For patients who suffer frequent sharp abdominal pain from chronic pancreatitis, antioxidants may offer effective pain relief, according to a study recently published in Gastroenterology, the journal of the American Gastroenterological Association Institute.
5 comments - Posted Jan 23, 2009
Hearts in the medical community beat with considerable excitement at the discovery of leptin in 1994. A hormone produced by fat, leptin has a very useful talent: it tells the brain when to stop eating. So hopes were high that leptin would become the basis of an anti-obesity treatment. What could be simpler than to dose an obese person with a hormone that says, "You're not hungry any more, and you want to stop eating."
0 comments - Posted Jan 22, 2009
According to biologists at the Baylor College of Medicine, limiting the copies of a gene that produces a protein affecting organ development serves to decrease fat cell size in mice, enhance their responsiveness to insulin, and increase their energy level.
0 comments - Posted Jan 14, 2009
Avandia (rosiglitazone) and Actos (pioglitazone), two medications used to lower blood sugar in type 2 patients, double the risk of fractures in women, but not in men, says a new study.
0 comments - Posted Dec 22, 2008
Metformin, the tried-and-true diabetes drug that is prescribed to many type 2s when they are first diagnosed, may decrease the risk of death from cardiovascular disease. That's the conclusion of a meta-analysis by researchers at the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland.
0 comments - Posted Nov 3, 2008
An experimental exenatide (Byetta)-like drug called liraglutide has shown the ability to enhance insulin and glucagon production and suppress appetite in type 2 patients, according to a report in the British medical journal The Lancet.
0 comments - Posted Oct 13, 2008
An aspirin-like drug discovered 132 years ago may prove to be a powerful weapon against type 2 diabetes.
3 comments - Posted Oct 13, 2008
The Food and Drug Administration is considering a requirement that before receiving agency approval, new diabetes treatment drugs must not only lower blood sugar levels, but also demonstrate a positive effect on heart disease and lifespan.
1 comment - Posted Jul 3, 2008
It seems too good to be true, but researchers from Queen Mary’s School of Medicine and Dentistry in London are advancing a new therapy to reduce the cardiovascular risk factors of high blood cholesterol, blood pressure, blood homocysteine levels, and platelet clumping—all in one pill.
0 comments - Posted Feb 1, 2004
When combined with NPH insulin taken at bedtime, Glucophage (metformin) provides slightly better glucose control with less weight gain and improved satisfaction with diabetes treatment than Prandin (repaglinide) plus NPH, say researchers in the United Kingdom.
0 comments - Posted Dec 1, 2002
Eli Lilly and Company of Indianapolis, Indiana, and Amylin Pharmaceuticals of San Diego, California, have formed a global agreement to collaborate on development and sale of a potential new treatment for type 2 diabetes.
0 comments - Posted Dec 1, 2002
Zyprexa (olanzapine), which belongs to a family of drugs known as atypical anti-psychotics, could be a factor in the development of diabetes.
0 comments - Posted Nov 1, 2002
Combination oral contraceptives may do more than prevent unwanted pregnancies—they also may help prevent diabetes.
0 comments - Posted Sep 1, 2002
Emisphere Technologies Inc., of Tarrytown, New Jersey announced the results of three phase I studies for two new medications for the oral delivery of insulin. Representatives, who presented the data at Investor Day In New York City and released a written statement on September 7, said the trials showed that the drugs were successfully absorbed from the gastrointestinal tract and significantly reduced blood glucose levels in study subjects.
0 comments - Posted Nov 1, 2001
Aspirin has been shown to help prevent heart disease among people with diabetes. The American Diabetes Association (ADA) has recommended the over-the-counter pain reliever to diabetic adults who have cardiovascular disease or are at risk for it.
0 comments - Posted May 1, 2001